1. Introduction {#sec1}
===============

To discover and develop novel natural compounds with therapeutic selectivity or that can preferentially kill cancer cells without significant toxicity to normal cells is an important area in cancer chemotherapy. Because of their wide range of biological activities and low toxicity in animal models, some natural products have been used as alternative treatments for cancers. Many anticancer drugs are derived from naturally occurring compounds. Vinca alkaloids (e.g., vinblastine, vincristine) and taxol are examples of such compounds.

The traditional Chinese medicine kushen is the dried roots of *Sophora flavescens*Aiton (Leguminosae). It was first described in the Chinese book *Shen Nong Ben Cao Jing* in 200 A.D. as a treatment for solid tumors, inflammation, and other diseases \[[@B1]\]. The traditional use of kushen includes the decoction or powder of dried plant roots. It is commonly used for the treatment of viral hepatitis, cancer, enteritis, viral myocarditis, arrhythmia, and skin diseases (e.g., colpitis, psoriasis, eczema) \[[@B2]\].

The known chemical components of kushen include alkaloids (3.3%), flavonoids (1.5%), alkylxanthones, quinones, triterpene glycosides, fatty acids, and essential oils \[[@B2], [@B3]\]. Kushen alkaloids (KS-As) and kushen flavonoids (KS-Fs) are well-characterized components in kushen. KS-As have been developed as anticancer drugs in China. More potent antitumor activities have been identified in KS-Fs than in KS-As \[[@B5]\].

2. KS-As {#sec2}
========

KS-As have been well studied and are considered to be the major active components of kushen as demonstrated in experimental animal models \[[@B6]--[@B9]\] and clinical studies \[[@B10]--[@B15]\]. The bioactivities of kushen (including antitumor, anti-viral and anti-inflammatory activities) have been shown in the KS-As fraction \[[@B7]\].

KS-As containing oxymatrine, matrine ([Figure 1](#fig1){ref-type="fig"}), and total alkaloids were approved for the treatment of cancer patients by the Chinese State Food and Drug Administration (SFDA) in 1992. Multiple KS-As products have been used widely in China for the treatment of cancers and hepatitis. The SFDA-approved KS drugs for oncology are all KS-As used as single agents or in combination with chemotherapy or radiotherapy. Few studies focused on the efficacy of KS-As in animal models and clinical trials before 1992, when KS-As was first approved.

Several clinical studies reported that KS-As were efficacious in the treatment of various types of solid tumors (including lung, liver, and gastrointestinal tract). The treatment responses were comparable to, or better than, that of chemotherapy drug-treated patients ([Table 1](#tab1){ref-type="table"}) \[[@B12], [@B15]--[@B69]\]. KS-As demonstrates a good safety profile in cancer patients, such as reduced toxicity in the bone marrow when used in combination with chemotherapy agents \[[@B33]\]. Long-term survival data for KS-As-treated cancer patients remains to be demonstrated with well-controlled clinical studies and large patient cohorts.

3. Matrine and Oxymatrine {#sec3}
=========================

Matrine and oxymatrine ([Figure 1](#fig1){ref-type="fig"}) are the two major alkaloid components found in the roots of Sophora species. They are obtained primarily from *Sophora japonica* (kushen), *Sophora subprostrata* (shandougen), and from the overground portion of *Sophora alopecuroides*. The matrines were first isolated and identified in 1958; they are unique tetracyclo-quinolizindine alkaloids found only in *Sophora* species thus far \[[@B34]--[@B38]\].

*In vitro* studies have demonstrated that matrine and oxymatrine weakly inhibit the growth of various human tumor cell lines with a half-maximal inhibitory concentration (IC~50~) of 1.0--4.0 mg/mL \[[@B39]--[@B43]\].

*In vivo* studies have shown that KS-As, oxymatrine, and matrine inhibit the growth of murine tumors, including H22, hepatoma, S180, sarcoma, and MA737 breast cancer cells \[[@B40], [@B42], [@B44], [@B45]\]. In a human xenograft tumor model using the SGC-7901 cell line, matrine enhanced the inhibition of 5-fluorouracil in the tumor \[[@B33]\].

Matrine can also inhibit the invasiveness and metastasis of the human malignant melanoma cell line A375 and cervical cancer HeLa cells, as well as induce differentiation of leukemia K-562 cells \[[@B46]--[@B48]\]. In addition, matrine-induced autophagy in rat C6 glioma cells has been observed by electron microscopy \[[@B49]\].

The antitumor response of KS-As was further demonstrated in several clinical studies in various types of cancers, including stomach, esophagus, liver, colon, lung, cervix, ovary, and breast cancers, as a single agent \[[@B10]--[@B15]\] or in combination with chemotherapy \[[@B16]--[@B19]\] or radiotherapy \[[@B50]\]. It has been reported that matrine exerts its antitumor effects by inhibiting the proliferation and inducing the apoptosis of gastric and cervical cancer cells as well as leukemic and glioma cells \[[@B53], [@B49]--[@B52]\].

Several *in vitro* and *in vivo* studies have tried to elucidate the mechanism of action of matrine. Matrine promotes apoptosis in leukemic \[[@B54]\], breast cancer \[[@B55]\], nonsmall-cell lung cancer \[[@B56]\], hepatocarcinoma, and gastric cancer cells \[[@B57]\] by a mitochondrial-mediated pathway \[[@B58]\]. Beclin 1 is involved in matrine-induced autophagy, and the pro-apoptotic mechanism of matrine may be related to its upregulation of Bax expression \[[@B58]\]. Recent evidence indicates that matrine also has appreciable effects in modulating the immune response by reducing the invasion and metastasis of HCC cells \[[@B59], [@B60], [@B61]\].

Tissue homeostasis requires a balance between the division, differentiation and death of cells. A tumor is a type of "cell cycle disorder" that has the abnormal interface of division, differentiation and death \[[@B62]\]. As a "biological modifier" of cells, matrine can reverse the abnormal biologic behavior of tumor cells and recover the balance between the division, differentiation, and death of cells.

Matrine can also inhibit the invasiveness and metastasis of the human malignant melanoma cell line A375 \[[@B63]\]. Some studies reported that matrine reduced the adhesion and migration of HeLa cells \[[@B64]\]. The mechanisms of action of matrine against cancer cell proliferation and invasion are associated with epidermal growth factorvascular endothelial growth factor vascular endothelial growth factor receptor 1 Akt--nuclear factor-kappa B (EGF/VEGF---VEGFR1---Akt---NF-*κ*B) signaling \[[@B55]\] ([Table 2](#tab2){ref-type="table"}).

Matrine displays synergistic effects with the anticancer agents celecoxib (cyclooxygenase-2 inhibitor), trichostatin A (histone deacetylase inhibitor) and rosiglitazone against the tumor proliferation and VEGF secretion. Matrine may have broad therapeutic and/or adjuvant therapeutic applications in the treatment of human nonsmall-cell lung cancer, breast cancer, and hepatoma \[[@B55], [@B56]\] ([Table 2](#tab2){ref-type="table"}).

Some studies have also reported upon the anticancer activity of oxymatrine in human gastric cancer cells, pancreatic cancer, and human breast cancer cells \[[@B65]--[@B67]\]. Oxymatrine can induce the apoptosis death of human pancreatic cancer cells, which might be attributed to the regulation of Bcl-2 and IAP families, release of mitochondrial cytochrome C, and activation of caspase-3 \[[@B66]\] ([Table 2](#tab2){ref-type="table"}).

Compound kushen injection (CKI), commonly known as Yanshu injection, is extracted from two herbs, kushen (Radix Sophorae Flavescentis) and Baituling (Rhizoma Smilacis Glabrae), with the primary components being oxymatrine and matrine \[[@B67]\]. CKI has been used extensively alone or in combination with chemotherapy or radiotherapy for many years in China. Clinical studies have shown that CKI attenuates the side effects of chemotherapy and radiotherapy by improving the quality of life and regulating the immune function of cancer patients, as well as synergizing the therapeutic effects of chemotherapy and radiotherapy ([Table 1](#tab1){ref-type="table"}) \[[@B16]--[@B69], [@B68]\]. It has been demonstrated that CKI suppresses the growth of tumor cells by inducing apoptosis and inhibiting the migration, invasion, and adhesion, of such cells \[[@B70]\].

Cancer stem cells (CSCs) play an important part in the initiation, relapse and metastasis of cancer. A specific agent has not been found to target CSCs because they are resistant to most conventional therapies and proliferate indefinitely. In one study, CKI suppressed the size of the side population (SP; \~90%) and downregulated the main genes of the Wnt signaling pathway in MCF-7 SP cells. CKI suppressed tumor growth by downregulating the Wnt/b-catenin pathway, whereas cisplatin activated the Wnt/b-catenin pathway and could spare SP cells. These data suggested that CKI may serve as a novel drug targeting CSCs, but further studies are recommended \[[@B71]\].

4. KS-Fs {#sec4}
========

The antitumor effects of some flavonoid compounds ([Figure 1](#fig1){ref-type="fig"}) have been demonstrated *in vitro* and *in vivo* \[[@B73]--[@B77]\]. Surprisingly, the antitumor activities of KS-Fs were more potent than those of KS-As, which have been considered to be the major active components in the plant \[[@B4]\]. KS-Fs such as kurarinone, 2′-methoxykurarinone, and sophoraflavanone G (lavandulyl flavanones isolated from *S. flavescens*) ([Figure 1](#fig1){ref-type="fig"}) can inhibit cell proliferation in A549, NCI-H460 (nonsmall-cell lung), SK-OV-3 (ovary), SK-MEL-2 (skin), XF498 (central nerve system), HCT-15 (colon) HL-60 (myeloid leukemia) and SPC-A-1 (lung) cells with IC~50~ values between 2 *μ*g/mL and 36 *μ*g/mL \[[@B75], [@B77], [@B4]\].

Antitumor efficacies were confirmed in mice models of H22, S180 and Lewis lung tumors as well as nude mice models of human H460 and Eca-109 xenografted tumors \[[@B79], [@B4]\]. Moreover, KS-Fs and kurarinone enhanced the antitumor activities of Taxol *in vitro* and *in vivo*\[[@B4], [@B78]\]. The oral or intravenous maximum tolerated dose of KS-Fs was \>2.8 g/kg or 750 mg/kg, respectively, appreciably more than the oral median lethal dose of KS-As (≤1.18 g/kg). Adverse reactions were not observed. In addition, peripheral blood cell counts were not significantly affected in normal mice treated with KS-Fs at 200 mg/kg/day for 2 weeks \[[@B79], [@B4]\].

Kuraridin, sophora flavanone G, kurarinone, kushenol F, and norkurarinol have extremely strong tyrosinase inhibitory activity \[[@B79]--[@B83]\]. Kurarinol, kuraridinol, and trifolirhizin markedly inhibited (\>50%) melanin synthesis \[[@B82], [@B83]\].

The mechanism of action of KS-Fs and kurarinone involves inhibition of tumor necrosis alpha one (TNF*α*l)-induced NF-*κ*B activation and enhance apoptosis \[[@B79], [@B84], [@B85]\]. The apoptosis-inducing effect was enhanced in the presence of taxol. In H460 xenograft mice treated with kurarinone, downregulation of Bcl-2 and upregulation of caspase 8 and caspase 3 in tumors were observed \[[@B79]\]. KS-Fs and kurarinone induce apoptosis in tumors by acting on multiple cellular targets, including inhibition of NF-*κ*B activation and multiple receptor tyrosine kinase activities \[[@B79]\]. Kurarinone and kuraridin attenuate NF-*κ*B activation by inhibition of I*κ*B*α* proteolysis and p65 nuclear translocation, as well as phosphorylation of extracellular signal-regulated kinase (ERK)1/2, c-Jun N-terminal kinase (JNK), and p38 mitogen-activated protein kinases \[[@B79], [@B85]\]. Constitutive NF-*κ*B and RSK2 activities are important hallmarks of human cancers (including hematopoietic malignancies and solid tumors), so prenylated flavanones represent an attractive class of natural inhibitors of the ERK/RSK2 signaling pathway for cancer therapy \[[@B86]\] ([Table 2](#tab2){ref-type="table"}).

Fifty-six flavonoids have been identified from KS-Fs. Twenty-one of the KS-Fs have been found to have antitumor activities. Studies have demonstrated that more potent antitumor activities are observed in KS-Fs instead of KS-As fractions. KS-Fs were more than 10-fold more potent than KS-As in the cell proliferation assay. Further evaluation of the safety and efficacy of KS-Fs in clinical oncology settings is warranted. KS-Fs could be developed as botanical drugs for solid tumors, and kurarinone could be used as a marker compound. Additional structural modifications of KS-Fs compounds could also generate more potent drug candidates.

5. Conclusions and Future Perspectives {#sec5}
======================================

This paper summarized the antitumor efficacy and mechanism of action of kushen and its constituents *in vitro* and *in vivo*. Many Patents of kushen extracts have been applied in USA, China and other countries ([Table 3](#tab3){ref-type="table"}). These results strengthen the hypothesis that kushen (or its components) alone or combination with chemotherapy agents could modulate various molecular pathways in tumors or be used to treat cancer. Studies described here and elsewhere highlight the use of flavonoids of kushen as novel chemoprevention agents for cancer intervention. It is expected that future studies with kushen will help to define various molecular mechanisms and targets for the inhibition and apoptosis of tumor cells. The number of multicenter, large sample, randomized, double-blind, controlled chemoprevention clinical trials with kushen are very limited. Extensive clinical research is warranted to evaluate further the safety and chemoprevention efficacy of kushen alone or in combination with chemotherapy agents.
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###### 

Clinical trials using compound kushen injection.

       Dose and course of treatment                                                               Combined medication                                                                                                                                             Case/control   Cancer type                                                                                        Indications and symptoms                                     Efficacy                                                                                                                                                               Positive control                                                                                                                                                                                                                                                                                                Side effect                          Reference
  ---- ------------------------------------------------------------------------------------------ --------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------- -------------------------------------------------------------------------------------------------- ------------------------------------------------------------ ---------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------ ------------
  1    1,000--1,500 mg + GS 500 mL, i.v., q.d., 30--45 days                                       No                                                                                                                                                              68/37          Gastric cancer                                                                                     Fever, pain, GI reactions, ascites                           Relief                                                                                                                                                                 MMC + UFT                                                                                                                                                                                                                                                                                                       Abdominal distention, constipation   \[[@B12]\]
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  2    1,000--1,500 mg + GS 500 mL, i.v., q.d., 30 days, total dose of 30--45 g                   No                                                                                                                                                              44             Hepatocarcinoma                                                                                    Evaluation of curative effect, immune effect, toxic effect   Effective treatment, reduction in tumor size, improvement in symptoms and signs, improvement in immune function                                                        No                                                                                                                                                                                                                                                                                                              Nausea                               \[[@B15]\]
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  3    30 mL + GS 250 mL, i.v., q.d., 10 days                                                     Hydroxycamptothecin                                                                                                                                             20/20          Hepatocellular carcinoma                                                                           Recurrence rate                                              HCPT and CKI postoperative arterial infusion may be helpful for reducing intrahepatic recurrence after curative resection for HCC                                      PDD and 5-FU                                                                                                                                                                                                                                                                                                    No                                   \[[@B16]\]
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  4    1,000 mg + GS 500 mL, i.v., q.d., 30 days                                                  Carboplatin or 5-FU                                                                                                                                             21             Malignant ascites                                                                                  Evaluation of curative effect (ascites)                      Lessening of ascites                                                                                                                                                   Carboplatin or 5-FU                                                                                                                                                                                                                                                                                             Abdominal distention                 \[[@B17]\]
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  5    50 mL intrapleural injection or 100 mL peritoneal injection, b.i.w., 3 weeks               Dexamethasone                                                                                                                                                   24             Virulent succus inside the thorax and belly: lung cancer, breast cancer, ovarian cancer            Ascites                                                      Lessening of ascites, effective rate (CR and PR) 68.8%                                                                                                                 No                                                                                                                                                                                                                                                                                                              Mild abdominal pain                  \[[@B18]\]
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  6    1,000 mg + GS 500 mL, i.v., q.d., 30 days, 2--4 cycles                                     MVP/FAM/CAF/FP                                                                                                                                                  65/61          Malignant tumor: lung, esophageal, liver, gastric, breast, colon, nasopharyngeal                   Toxic effect, QoL                                            Improvement in QoL, reduce the toxic effects (leukopenia, GI reactions) of chemotherapy                                                                                MVP/FAM/CAF/FP                                                                                                                                                                                                                                                                                                  No                                   \[[@B19]\]
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  7    12--15 mL + NS 250 mL, i.v., q.d., 10 days                                                 No                                                                                                                                                              52/52          Malignant tumor: lung, breast, gastric, esophageal, colorectal, pancreatic                         Pain                                                         Pain relief                                                                                                                                                            Sustained-release indomethacin or tramadol hydrochloride                                                                                                                                                                                                                                                        No                                   \[[@B20]\]
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  8    15 mL + NaCl 250 mL, i.v., q.d., for 12 days                                               Fentanyl                                                                                                                                                        31/31          Advanced cancer: gastric, esophageal, breast                                                       Pain                                                         Pain relief and KPS better than fentanyl, *P* \< 0.05                                                                                                                  Fentanyl alone                                                                                                                                                                                                                                                                                                  No                                   \[[@B21]\]
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  9    20 mL + NaCl 250 mL, i.v., q.d., for 14 days, 3 cycles                                     Oxaliplatin and capecitabine                                                                                                                                    36/30          Advanced gastric cancer in senile subjects                                                         KPS; toxic effect                                            KPS better than oxaliplatin and capecitabine, *P* \< 0.05; CKI has a low incidence rate for leukopenia, pain and hepatotoxicity, *P* \< 0.05                           Oxaliplatin and capecitabine                                                                                                                                                                                                                                                                                    No                                   \[[@B22]\]
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  10   20 mL, i.v., q.d., 10--14 days                                                             Chemotherapy: CAVP or CAP                                                                                                                                       61/60          Lung cancer                                                                                        Immune                                                       Improvement in immune function                                                                                                                                         Chemotherapy: CAVP or CAP                                                                                                                                                                                                                                                                                       No                                   \[[@B23]\]
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  11   30 mL + NaCl 250 mL, i.v., q.d., 7 days                                                    Taxol and epirubicin                                                                                                                                            34/34          Breast cancer                                                                                      Immune                                                       Improvement in immune function                                                                                                                                         Taxol and epirubicin                                                                                                                                                                                                                                                                                            No                                   \[[@B24]\]
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  12   20 mL + GS/NaCl 250 mL, i.v., q.d., 14 days, 2 cycles                                      TACE (5-FU 1,000--2,000 mg, MMC 10--20 mg, EP I60--100 mg)                                                                                                      27/23          Liver cancer                                                                                       KPS; toxic effect                                            KPS better than TACE, *P* \< 0.05; The incidence rate of nausea and vomiting hepatotoxicity were significantly lower than for TACE chemotherapy, *P* \< 0.05           TACE                                                                                                                                                                                                                                                                                                            No                                   \[[@B25]\]
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  13   30 mL + GS/NaCl 250 mL, i.v., q.d., 10 days, 4 cycles                                      FOLRIRI chemotherapy                                                                                                                                            50/50          Advanced colorectal cancer                                                                         Pain, toxic effect, KPS                                      Pain relief, reduced toxic effect (leukopenia, GI reactions, hepatotoxicity and renal toxicity) of FOLFIRI chemotherapy; improved QoL                                  FOLRIRI chemotherapy                                                                                                                                                                                                                                                                                            No                                   \[[@B26]\]
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  14   20 mL, i.v., q.d., 14 days, 3 cycles                                                       Radiotherapy                                                                                                                                                    33/33          Cervical cancer                                                                                    Evaluation of curative effect, KPS, immune toxic effect      Improve therapeutic effects, QoL, immune function; attenuate myelosuppression                                                                                          Radiotherapy alone                                                                                                                                                                                                                                                                                              No                                   \[[@B27]\]
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  15   10 mL + NaCl 250 mL i.v. q.d. 10 days                                                      DA/TA/MA chemotherapy                                                                                                                                           35/35          AML                                                                                                KPS, hematotoxicity                                          Improve QoL; attenuate hematotoxicity (leukopenia) of chemotherapy                                                                                                     DA/TA/MA chemotherapy                                                                                                                                                                                                                                                                                           No                                   \[[@B28]\]
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  16   20 mL intrapleural injection; keep 48 h q2W and 20 mL + 100 mL NaCl, i.v., q.d., 4 weeks   No                                                                                                                                                              32/32          Malignant pleural effusion                                                                         KPS, evaluation of curative effect, toxic effect             Improve QoL and therapeutic effects; reduce toxic effects                                                                                                              Cisplatin                                                                                                                                                                                                                                                                                                       No                                   \[[@B29]\]
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  17   100 mL, i.v. b.i.d., 10 days                                                               Gastric cancer: TPF chemotherapy; colorectal cancer: FOLFOX or FOLFRI chemotherapy; breast cancer: TA or CAF chemotherapy; lung cancer: GP/TP/NP chemotherapy   83/83          Malignant tumors: gastric, lung, colorectal, breast                                                Hepatotoxicity                                               CKI can effectively prevent hepatic injury caused by chemotherapy (incidence and degree of hepatic injuries)                                                           Chemotherapy: gastric cancer: TPF; colorectal cancer FOLFOX or FOLFRI; breast cancer: TA or CAF; lung cancer GP/TP/NP                                                                                                                                                                                           No                                   \[[@B30]\]
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  18   20 mL + NaCl 250 mL, i.v., q.d., 21 days, 2 cycles                                         FOLFOX4 chemotherapy                                                                                                                                            27/21          Gastric cancer                                                                                     Toxic effect                                                 Incidence rate of alopecia lower than for FOLFOX4 chemotherapy, *P* \< 0.05.                                                                                           FOLFOX4 chemotherapy                                                                                                                                                                                                                                                                                            No                                   \[[@B31]\]
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  19   20 mL + NaCl 200 mL, i.v., q.d., 14 days, 2 cycles                                         FOLFX chemotherapy                                                                                                                                              30/30          Gastric cancer                                                                                     Toxic effect, QoL, symptoms                                  Promote reduction of symptoms, reduce chemotherapy side effects (alopecia, leukopenia, thrombocytopenia, GI reactions), improve QoL and prolong median survival time   FOLFX chemotherapy                                                                                                                                                                                                                                                                                              No                                   \[[@B32]\]
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  20   20 mL in NaCl 250 mL, i.v., q.d., for 3-4 weeks, 2-3 cycles                                Chemotherapy and radiotherapy                                                                                                                                   75/75          Mid-late-stage cancer: lung, breast, esophageal, nasopharyngeal, colorectal, pancreatic, ovarian   Immune, CBR, KPS, toxic effect                               Improvement in immune function, increase the CBR and QoL and reduce adverse reactions of chemotherapy in patients with midlate-stage cancer.                           Chemotherapy and radiotherapy (lung cancer: NP/GP/TP + radiotherapy; breast cancer: CAF/TA + radiotherapy: esophageal cancer: PF + radiotherapy; nasopharyngeal carcinoma: DDP + radiotherapy; colorectal cancer: oxaliplatin + 5FU + CF/oxaliplatin + xeloda; pancreatic cancer: GP; ovarian cancer: CAP/TP)   No                                   \[[@B69]\]

AML: acute myeloid leukemia; CAF: cyclophosphamide, adriamycin, and fluorouracil; CAP: cyclophosphamide, doxorubicin, and cisplatin; CAVP: cyclophosphamide, doxorubicin, and etoposide; CBR: clinical benefit rate; CF: calcium 5-formyletrahydrofolate; CR: complete remission; DA: daunorubicin and cytarabine; DDP: cisplatin; FAM: fluorouracil, adriamycin, and mitomycin; FOLFOX: oxaliplatin, calcium folinate, and fluorouracil; FOLFOX4: oxaliplatin, calcium folinate and fluorouracil; fOLFRI: irinotecan, calcium folinate and fluorouracil; FOLFX: oxaliplatin, calcium folinate and fluorouracil; FOLRIRI: leucovorin, fluorouracil, and irinotecan; FP: fluorouracil and cisplatin; 5-FU: fluorouracil; GI: gastrointestinal; GP: gemcitabine and cisplatin; HCC: hepatocellular carcinoma; HCPT: hydroxycamptothecin; KPS: karnofsky performance scale; MA: mitoxantrone and cytarabine; MMC: mitomycin; MVP: mitomycin, vinblastine, and cisplatin; NP: vinorelbine and cisplatin; PDD: cisplatin; PR: partial remission; QoL: quality-of-life; TA: paclitaxel and epirubicin; TA(9): pirarubicin and cytarabine; TACE: fluorouracil, mitomycin, and epirubicin; TP: paclitaxel and cisplatin; TPF: paclitaxel, fluorouracil, and cisplatin; UFT: Tegafur-Uracil.

###### 

Mechanism of action of the chemotherapy of kushen compounds.

  Compound                                                                  Mechanisms of action                                                                                                                                              Reference
  ------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------
  Matrine                                                                   Promotes apoptosis via mitochondria                                                                                                                               \[[@B53]--[@B57]\]
  Modulates the immune response                                             \[[@B58]--[@B60]\]                                                                                                                                                
  Inhibits EGF/VEGF---VEGFR1---Akt---NF-*κ*B signaling                      \[[@B54], [@B62], [@B63]\]                                                                                                                                        
  Compound kushen injection                                                 Inhibits cancer stem cells                                                                                                                                        \[[@B71]\]
  Kuraridin, sophoraflavanone G, kurarinone, kushenol F, and norkurarinol   Strong tyrosine kinase inhibitory activity                                                                                                                        \[[@B79]--[@B83]\]
  Kurarinone                                                                Inhibits TNF*α*l-induced NF-*κ*B activation and enhances apoptosis                                                                                                \[[@B79], [@B84], [@B85]\]
  Kurarinone and kuraridin                                                  Attenuate NF-*κ*B activation by inhibition of I*κ*B*α* proteolysis and p65 nuclear translocation as well as phosphorylation of ERK1/2, JNK, and p38 MAP kinases   \[[@B79], [@B85]\]

###### 

Patents of kushen extracts.

  Patent                                                                                                                                         Patent number
  ---------------------------------------------------------------------------------------------------------------------------------------------- --------------------
  Extract of *Sophora flavescens* flavonoids and uses thereof                                                                                    US20050226943
  Prenylated flavonoid derivatives having anti-inflammatory properties and *Sophora flavescens* extracts                                         Korea1020000077932
  Extract of *Sophora flavescens* flavonoids and uses thereof                                                                                    US20050226943
  Compositions comprising matrine and dictamnine for treating or preventing cancer and other diseases                                            US2004192579A1
  Medicine preparation containing matrine or epimatrine and its application in analgesic medicines                                               CN1347694A
  Use of oxidized matrine in preparation of chemicals for treating venereal diseases                                                             CN1530108A
  A process for the manufacture of a herbal composition comprising a matrine                                                                     WO02067955A3
  Use of oxidized matrine in preparation of chemicals for treating viral myocarditis                                                             CN1530109A
  Double salt formed by inosine and matrine or oxymatrine and application thereof in field of medications                                        CN101724002A
  Pharmaceutical purpose of compound comprising ferulic acid and matrine alkaloid in prevention and treatment of osteoarthropathy                CN101669946A
  Application of oxidized matrine in preparing medicine for treatment of hepatitis B                                                             CN1157717A
  Joint synergy of ferulic acid and matrine alkaloid and medical application thereof                                                             CN101669945A
  Medicinal use of matrine alkaloid for promoting digestive tract power                                                                          CN1850075A
  Medicine composition containing silymarin and kurarinone or matrine and use thereof                                                            CN101357129A
  Pharmaceutical composition comprising kurarinone, magnolia vine fruit, and ginseng for treating hepatitis                                      CN1970001A
  Use of kurarinone in preparation of medicine for postoperative intestine functional restoration                                                CN1923198A
  Combination of medication of containing kurarinone and glycyrrhetic acid, and application                                                      CN1695624A
  Oxymatrine compositions and related methods for treating and preventing chronic infectious diseases                                            US2010022575A1
  Pharmaceutical composition comprising oxymatrine and baicalin                                                                                  CN1919205A
  Medicinal composition of oxymatrine and polysaccharide                                                                                         CN101081240A
  Complex salt of silybin and oxymatrine or matrine and uses thereof                                                                             CN101157689A
  Double salt formed by inosine and matrine or oxymatrine and application thereof in field of medications                                        CN101724002A
  Method for separating matrine and oxymatrine from total matrines                                                                               CN101585837A
  Application of oxymatrine in preparing medicine for treating acute chronic cardiac insufficiency disease                                       CN101185647A
  Application of oxymatrine in preparing medicine to treat viral hepatitis C                                                                     CN1350848A
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